Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Katherine L. Nathanson, MD

Katherine L. Nathanson, MD Physician

Professor of Medicine
Professor of Genetics

Languages spoken:

  • French

Dr. Nathanson is a Penn Medicine employed physician.

Clinical Specialties

Specialty:

  • Medicine
    • Medical Genetics

Programs & Centers:

Board Certification:

  • Medical Genetics, 1999

Clinical Expertise:

  • Acoustic Neuromas
  • Birt-Hogg-Dubé Syndrome
  • Cancer Genetic Testing
  • Genetic and Rare Diseases Treatments and Procedures
  • Genetic Counseling
  • Genetic Skin Disorders
  • Genetic Testing
  • Hereditary Cancer Syndrome
  • Hereditary Papillary Renal Cancer
  • Klinefelter Syndrome
  • Li-Fraumeni Syndrome
  • Neurofibromatosis Type 1 (NF1)
  • Paragangliomas
  • Pheocromocytoma
  • Schwannomatosis
  • Tuberous Sclerosis
  • Von Hippel Lindau Syndrome (VHL)

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Beth Israel Deaconess Medical Center
Fellowship: Children's Hospital of Philadelphia

Memberships

American Association for Cancer Research, National American Association for the Advancement of Science, National American College of Medical Genetics, National American College of Physicians, National American Society for Clinical Investigation, National American Society for Human Genetics, National Breast Cancer Information Core Steering Committee, National Melanoma Research Breakthrough Consortium, National Movember GAP5 Translational Research Steering Committee (Testicular Cancer), International National Cancer Institute Blue Ribbon Panel Working Group - Tumor Evolution and Progression, National National Institutes of Health, Cancer Genetics Study Section, National National Institutes of Health, National Cancer Institute Loan Repayment Program Study Section, National TCGA Pheochromocytoma/Paraganglioma Disease Working Group, National TCGA Testicular Germ Cell Tumor Working Group, National Cancer Institute, National Tuberous Sclerosis Alliance, National

Hospital Affiliation

Dr. Nathanson is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Dr. Nathanson’s research focuses on the genetics of human cancer, both germline changes which confer susceptibility to cancer and somatic genetic changes associated with outcome.

Her research projects fall into several areas:

1) Identification and characterization of germline genetic changes associated with breast cancer susceptibility. These projects utilize two sample sets, a large clinical database of high risk breast cancer patients and a case-control study of white and black patients with breast cancer. Currently the projects in the laboratory focus on resequencing of BRCA1-associated genes as candidate breast cancer susceptibility genes in patients with high risk breast cancer and studying copy number variation as associated with potential susceptibility to high risk breast cancer in families with multiple cases of breast cancer.

2) Identification of genetic changes associated with testicular cancer susceptibility in case-control sample set. Dr. Nathanson recently completed a successful genome wide association study in testicular cancer, and is in the process of designing and doing a number of follow-up studies.

3) Identification of somatic genetic markers in melanoma as determinants of response to therapy. The projects in the laboratory focus on several aspects of melanoma genetics including genotyping patients to determine targeted therapy selection, using genetics and genomics to sub-set melanomas, as well as understand response to therapy, and identify novel genes important in melanoma progression.

Selected Publications:

Qian F, Feng Y, Zheng Y, Ogundiran TO, Ojengbede O, Zheng W, Blot W, Ambrosone CB, John EM, Bernstein L, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Press MF, Nathanson KL, Hennis A, Nemesure B, Ambs S, Kolonel LN, Olopade OI, Haiman CA, Huo D: Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Hum Genet 135 (19): 1145-1159,2016.

Balmaña J, Digiovanni L, Gaddam P, Walsh MF, Joseph V, Stadler ZK, Nathanson KL, Garber JE, Couch FJ, Offit K, Robson ME, Domchek SM.: Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. J Clin Oncol : 2016.

Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Bandera EV, Barile M, Barkardottir RB, Barrowdale D, Beckmann MW, Benitez J, Berchuck A, Bisogna M, Bjorge L, Blomqvist C, Blot W, Bogdanova N, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Børresen-Dale AL, Brauch H, Brennan P, Brenner H, Bruinsma F, Brunet J, Buhari SA, Burwinkel B, Butzow R, Buys SS, Cai Q, Caldes T,: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7 : 12675,2016.

Krepler C, Xiao M, Samanta M, Vultur A, Chen HY, Brafford P, Reyes-Uribe PI, Halloran M, Chen T, He X, Hristova D, Liu Q, Samatar AA, Davies MA, Nathanson KL, Fukunaga-Kalabis M, Herlyn M, Villanueva J.: Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget : 2016.

Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, Offit K, Robson ME: Counseling framework for moderate penetrance cancer susceptibility mutations. Nat Rev Clin Oncol 13 (9): 581-8,2016.

Vijai J, Topka S, Villano D, Ravichandran V, Maxwell KN, Maria A, Thomas T, Gaddam P, Lincoln A, Kazzaz S, Wenz B, Carmi S, Schrader KA, Hart SN, Lipkin SM, Neuhausen SL, Walsh MF, Zhang L, Lejbkowicz F, Rennert H, Stadler ZK, Robson M, Weitzel JN, Daly MJ, Couch FJ, Nathanson KL, Norton L, Rennert G, Offit K.: A recurrent ERCC3 truncating mutation confers moderate risk for breast cancer. Cancer Discov. : 2016.

Huo D, Feng Y, Haddad S, Zheng Y, Yao S, Han YJ, Ogundiran TO, Adebamowo C, Ojengbede O, Falusi AG, Zheng W, Blot W, Cai Q, Signorello L, John EM, Bernstein L, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Press MF, Deming SL, Rodriguez-Gil JL, Nathanson KL, Domchek SM, Rebbeck TR, Ruiz-Narváez EA, Sucheston-Campbell LE, Bensen JT, Simon MS, Hennis A, Nemesure B, Leske MC, Ambs S, Chen LS, Qian F, Gamazon ER, Lunetta KL, Cox NJ, Chanock SJ, Kolonel LN, Olshan AF, Ambrosone CB, Olopade OI, Palmer JR,: Genome-wide Association Studies in Women of African Ancestry Identified 3q26.21 as a Novel Susceptibility Locus for Estrogen Receptor Negative Breast Cancer. Hum Mol Genet : 2016.

Scelo G, Hofmann JN, Banks RE, Bigot P, Bhatt RS, Cancel-Tassin G, Chew SK, Creighton CJ, Cussenot O, Davis IJ, Escudier B, Frayling TM, Häggström C, Hildebrandt MA, Holcatova I, Johansson M, Linehan WM, McDermott DF, Nathanson KL, Ogawa S, Perlman EJ, Purdue MP, Stattin P, Swanton C, Vasudev NS, Wu X, Znaor A, Brennan P, Chanock SJ: International cancer seminars - A focus on kidney cancer. Ann Oncol 27 (8): 1382-1385,2016.

Maxwell KN, Domchek SM, Nathanson KL, Robson ME: Population Frequency of Germline BRCA1/2 Mutations. J Clin Oncol : 2016.

Hart SN, Maxwell KN, Thomas T, Ravichandran V, Wubberhorst B, Klein RJ, Schrader K, Szabo C, Weitzel JN, Neuhausen SL, Nathanson K, Offit K, Couch FJ, Vijai J: Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. Brief Bioinform 17 (4): 672-677,2016.

Academic Contact Info

351 BRB II/III
421 Curie Blvd
University of Pennsylvania

Philadelphia, PA 19104
Phone: (215) 662-4740
Patient appointments: 800-789-PENN (7366)

Related Links